Overview

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Status:
Recruiting
Trial end date:
2021-12-05
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Bortezomib
Cyclophosphamide
Epirubicin
Etoposide
Etoposide phosphate
Prednisone